Join
Aravive Inc. logo

ARAV

NASDAQ

Aravive Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2014
$0.04-0.01 (-12.58%)
News25/Ratings2

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Latest news

25 items

ARAV FAQ

7 questions
  • What does Aravive Inc. do?
    Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling...
  • Where does ARAV stock trade?
    Aravive Inc. (ARAV) is listed on NASDAQ.
  • What sector and industry is ARAV in?
    Aravive Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Aravive Inc. go public?
    Aravive Inc. (ARAV) completed its IPO in 2014.
  • What are analysts saying about ARAV?
    Aravive Inc. has had 2 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1200.00 price target on 2023-04-17. Recent price targets range from $1200.00 to $1500.00.
  • What companies are similar to ARAV?
    Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ARAV side-by-side with any of them on Quantisnow.
  • How can I track ARAV on Quantisnow?
    Quantisnow aggregates Aravive Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARAV to receive live email and push alerts on every new disclosure.